To the Editor: A transdermal TM-V (scopolamine) programmed-delivery system has recently been released as treatment for the prevention of nausea and vomiting associated with motion sickness. The National Registry of Drug-Induced Ocular Side Effects has had five case reports of adverse ocular effects secondary to this drug-delivery system. Two of the reported cases were bilateral mydriasis causing bilateral narrow-angle glaucoma. One patient required surgery; the other was treated medically. Since this medication is now often used on ships by those susceptible to motion sickness, physicians aboard ships should have available 4 per cent topical ocular pilocarpine and 0.25 per.
ASJC Scopus subject areas